DGAP-News: MeVis Medical Solutions AG / Key word(s): Half Year Results MeVis Medical Solutions AG Q2 2016: Operative stability at a high level 23.08.2016 / 08:30 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Again improvement in revenues in the Digital Mammography segment - Revenues in the second quarter with EUR 3.8 m almost identical to previous year ( EUR 3.7 m) - Earnings before interest and taxes (EBIT) in the second quarter with EUR 1.1 m also at level of previous year, 29 % EBIT-margin - Financial result increased slightly in the second quarter compared to previous year from EUR 0.3 m to EUR 0.5 m Bremen, August 23, 2016 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its figures for the first half of 2016. Sales in the second quarter of 2016 amounted to EUR 3,795 k, up 2 % compared to the same quarter in 2015 (EUR 3,730 k). As a result, sales rose year on year to EUR 7,671 k (prev. year: EUR 7,138 k) in the first half of the year. Sales in the new license business fell by 2 % to EUR 3,246 k, while sales in the maintenance business grew by 25 % to EUR 3,839 k, now accounting for 50 % of total sales. Sales in the Digital Mammography segment were up by 8 % to EUR 6,114 k (prev. year: EUR 5,637 k), while sales in the Other Diagnostics segment grew slightly by 4 % to EUR 1,557 k (prev. year: EUR 1,501 k). Operating costs increased in the second quarter of 2016 due to slightly higher staff costs, which were up 4 % in the second quarter among other things on account of new hires. This corresponds to a cumulative increase of 1 % in the first half of the year. In the second quarter, other operating expenses rose marginally year on year to EUR 474 k (prev. year: EUR 453 k). Cumulated for the first half of 2016, other operating expenses remained stable year on year. Depreciation and amortization came to EUR 899 k (down 14 % year on year, primarily due to lower scheduled write-downs on capitalized development costs), resulting in EBIT (earnings before interest and taxes) of EUR 2,293 k (up a significant 41 % on the previous year's figure of EUR 1,627 k) for the reporting period and a corresponding EBIT margin of 30 % (prev. year: 23 %). The financial result decreased from EUR 428 k year on year to EUR -367 k. Negative effects from the development of the US dollar exchange rate, combined with a high share of liquidity in US dollars, were largely responsible for this. Due to the fiscal unity, which became effective as of January 1, 2016, the tax expense consisted solely of capital income tax amounting to EUR 5 k (prev. year: tax expense of EUR 787 k). After-tax earnings consequently rose by EUR 653 k to EUR 1,921 k, which is equivalent to undiluted earnings per share of EUR 1.06 (prev. year: EUR 0.72). --------------------------------------------------------------------------- 23.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: MeVis Medical Solutions AG Caroline-Herschel-Str. 1 28359 Bremen Germany Phone: +49 421 224 95 0 Fax: +49 421 224 95 999 E-mail: [email protected] Internet: http://www.mevis.de ISIN: DE000A0LBFE4 WKN: A0LBFE Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 494893 23.08.2016